Evidence map›Paper›PMID 42768232›Full record

ArticleThe AAPS journal2026

Benchmarking Automated Mass Photometry against SEC-MALS and AUC for Quantifying Cross-Linked Monoclonal Antibody Aggregates.

Mingyue Li, Sharon Polleck, Cliff Entrican, Cassandra Larkin, Brenda Watt, Elizabeth McCoy

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in The AAPS journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mingyue LiAnalytical Research & Development, BioTherapeutics Pharmaceutical Sciences, Pfizer Inc. 1 Burtt Rd., Andover, Massachusetts, 01810, USA. mingyue.li2@pfizer.com.ORCID http://orcid.org/0000-0001-5760-8429
Sharon PolleckAnalytical Research & Development, BioTherapeutics Pharmaceutical Sciences, Pfizer Inc. 1 Burtt Rd., Andover, Massachusetts, 01810, USA.
Cliff EntricanAnalytical Research & Development, BioTherapeutics Pharmaceutical Sciences, Pfizer Inc. 1 Burtt Rd., Andover, Massachusetts, 01810, USA.
Cassandra LarkinAnalytical Research & Development, BioTherapeutics Pharmaceutical Sciences, Pfizer Inc. 1 Burtt Rd., Andover, Massachusetts, 01810, USA.
Brenda WattRefeyn Inc, 21 Hickory Dr., Suite 200 A Waltham, Waltham, Massachusetts, 02451-1034, USA.ORCID http://orcid.org/0009-0001-0174-7849
Elizabeth McCoyAnalytical Research & Development, BioTherapeutics Pharmaceutical Sciences, Pfizer Inc. 1 Burtt Rd., Andover, Massachusetts, 01810, USA.ORCID http://orcid.org/0009-0007-1435-1687

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monoclonal antibodies (mAbs) play pivotal roles in modern biotherapeutics, offering targeted treatments for diseases such as cancers and autoimmune disorders. However, antibody self-association and propensity for aggregation can potentially compromise intended efficacy and pose safety concerns, necessitating robust analytical methods for aggregate detection and quantification. Traditional techniques like Size Exclusion Chromatography with Multi-angle Light Scattering (SEC-MALS) and analytical ultracentrifugation-sedimentation velocity (AUC-SV) are widely used but are limited by long analysis times, large sample requirements, and potential artifacts. Mass photometry (MP), a novel single-molecule technique, measures the interferometric scattering signal arising from molecules binding and unbinding to a glass slide. This study compares automated MP with SEC-MALS and AUC-SV for mAb aggregation analysis, demonstrating that MP equipped with automated sample handling delivers accurate and consistent analysis for the main and subpopulation species comparable to these established methods. Specifically, MP can not only determine the molecular mass distribution but also provide quantitative analysis of the monomer and High Molecular Mass Species (HMMS) generated with chemical cross-linking. When quantifying cross-linked HMMS of an IgG mAb, MP quantitation shows linear correlation with the SEC method, while MP provided superior resolution and dynamic range compared to SEC-MALS. Furthermore, MP and AUC-SV show comparable resolution in differentiating higher order aggregates and exhibit linear correlation for dimer quantitation, the primary form of mAb HMMS. With the capability to differentiate mAb monomers from various oligomeric forms, MP may represent a new approach that offers significant advantages in efficiency and throughput in quantification and characterization of mAb HMMS.

Indexed as

Antibodies, MonoclonalChromatography, GelPhotometryProtein AggregatesCross-Linking ReagentsHumansMolecular WeightUltracentrifugationAntibodies, MonoclonalCross-Linking ReagentsProtein Aggregatesanalytical ultracentrifugationantibody aggregationhigh molecular mass speciesmass photometrymonoclonal antibodysize exclusion chromatography

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.